CRISPR Therapeutics AG (CRSP) Stock Analysis
Healthcare · Biotechnology
Sell if holding. Engine safety override at $47.73: Quality below floor (1.8 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.7/10 and A.R:R 5.2:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 27%; Below-average business quality; Negative price momentum.
CRISPR Therapeutics is a biopharmaceutical company developing CRISPR/Cas9 gene-editing therapies across hemoglobinopathies, in vivo liver editing, CAR T cell therapy, and regenerative medicine. CASGEVY (co-developed and co-commercialized with Vertex Pharmaceuticals) is the... Read more
Sell if holding. Engine safety override at $47.73: Quality below floor (1.8 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.7/10 and A.R:R 5.2:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 27%; Below-average business quality; Negative price momentum. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Score 5.7/10, moderate confidence.
Passes 7/9 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news boost analyst 0.40, earnings proximity 83d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and death cross (50MA < 200MA). Suitability: aggressive.
Recent Developments — CRISPR Therapeutics AG
Latest news
- Bernstein Maintains Market Perform on CRISPR Therapeutics, Raises Price Target to $56 — benzinga May 13, 2026 positive
- Citigroup Maintains Buy on CRISPR Therapeutics, Raises Price Target to $82 — benzinga May 6, 2026 positive
- CRISPR Therapeutics Q1 EPS $(1.28) Misses $(1.20) Estimate, Sales $1.458M Miss $2.700M Estimate — benzinga May 4, 2026 negative
Generated 2026-05-20T20:21:21Z.
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
2 floor-breakers·2 ceiling hits
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $47.73: Quality below floor (1.8 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.7/10 and A.R:R 5.2:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 27%; Below-average business quality; Negative price momentum. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Prior stop was $45.51. Score 5.7/10, moderate confidence.
Take-profit target: $74.54 (+56.6% upside). Prior stop was $45.51. Stop-loss: $45.51.
Quality below floor (1.8 < 4.0).
CRISPR Therapeutics AG trades at a P/E of N/A (forward -12.1). TrendMatrix value score: 9.0/10. Verdict: Sell.
35 analysts cover CRSP with a consensus score of 3.9/5. Average price target: $83.
What does CRISPR Therapeutics AG do?CRISPR Therapeutics is a biopharmaceutical company developing CRISPR/Cas9 gene-editing therapies across...
CRISPR Therapeutics is a biopharmaceutical company developing CRISPR/Cas9 gene-editing therapies across hemoglobinopathies, in vivo liver editing, CAR T cell therapy, and regenerative medicine. CASGEVY (co-developed and co-commercialized with Vertex Pharmaceuticals) is the world's first approved CRISPR-based therapy, approved for sickle cell disease and transfusion-dependent beta thalassemia.